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ABSTRACT
Objective: Clinicians predominantly use clinical
features to differentiate type 1 from type 2 diabetes yet
there are no evidence-based clinical criteria to aid
classification of patients. Misclassification of diabetes
is widespread (7–15% of cases), resulting in patients
receiving inappropriate treatment. We sought to identify
which clinical criteria could be used to discriminate
type 1 and type 2 diabetes.
Design: Systematic review of all diagnostic accuracy
studies published since 1979 using clinical criteria to
predict insulin deficiency (measured by C-peptide).
Data sources: 14 databases including: MEDLINE,
MEDLINE in Process and EMBASE. The search strategy
took the form of: (terms for diabetes) AND (terms for
C-Peptide).
Eligibility criteria: Diagnostic accuracy studies of
any routinely available clinical predictors against a
reference standard of insulin deficiency defined by cut-
offs of C-peptide concentrations. No restrictions on
race, age, language or country of origin.
Results: 10 917 abstracts were screened, and 231 full
texts reviewed. 11 studies met inclusion criteria, but
varied by age, race, year and proportion of participants
who were C-peptide negative. Age at diagnosis was the
most discriminatory feature in 7/9 studies where it was
assessed, with optimal cut-offs (>70% mean sensitivity
and specificity) across studies being <30 years or
<40 years. Use of/time to insulin treatment and body
mass index (BMI) were also discriminatory. When
combining features, BMI added little over age at
diagnosis and/or time to insulin (<1% improvement in
classification).
Conclusions: Despite finding only 11 studies, and
considerable heterogeneity between studies, age at
diagnosis and time to insulin were consistently the
most discriminatory criteria. BMI, despite being widely
used in clinical practice, adds little to these two
criteria. The criteria identified are similar to the Royal
College of General Practitioners National Health Service
(RCGP/NHS) Diabetes classification guidelines, which
use age at diagnosis <35 years and time to insulin
<6 m. Until further studies are carried out, these
guidelines represent a suitable classification scheme.
Systematic review registration: PROSPERO
reference CRD42012001736.
BACKGROUND
Correct classiﬁcation of a patient’s diabetes is
crucial for ensuring they receive the most
appropriate treatment and management.
Current guidelines for the treatment of dia-
betes are speciﬁc to type 1 and type 2 dia-
betes (T1D and T2D) and these show
marked differences,1–4 reﬂecting the differ-
ence in endogenous insulin production
between the two subtypes. Patients with T1D
rapidly develop severe insulin deﬁciency,
leading to high glycemic instability and so
require accurate insulin replacement (such
as multiple injections and carbohydrate
counting), and have poor response to non-
insulin therapies.3 5 Patients with T2D still
Strengths and limitations of this study
▪ We have carried out a comprehensive and robust
systematic review in accordance with PRISMA
guidelines and our initial published protocol.
▪ We screened a large number of literature
sources, and all reviewing and data extraction
was carried out in duplicate independently by
two authors (BS and JP).
▪ Considerable heterogeneity across studies pre-
cluded a formal meta-analysis.
▪ A limited number of studies were found meaning
there is still considerable uncertainty around cri-
teria for classification of type 1 and type 2
diabetes.
▪ Variability in the reference standard of insulin
deficiency across studies also led to further
uncertainty around findings limiting direct useful-
ness of criteria.
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continue to produce substantial amounts of their own
insulin, and, therefore, respond to non-insulin therapy,
have more stable glycaemia and, if insulin treatment is
needed, may achieve good control with non-
physiological insulin regimes.6 7
Currently, there are no published, evidence-based,
guidelines or criteria for diabetes classiﬁcation, despite
the importance for patient management. Guidance on
the classiﬁcation of the two types of diabetes from major
health organisations is limited, and focuses on aeti-
ology,8 9 whereas it is insulin production that is the
driver for informing treatment decisions. Insulin deﬁ-
ciency/production can be assessed by measurement of
C-peptide in either blood or urine,10 but it is rarely mea-
sured in clinical practice and current guidelines for dia-
betes management do not recommend its routine
use.1 3 11 Classiﬁcation is based primarily on clinical
judgement, with younger slimmer patients tending to be
classed as T1, and older, more obese patients diagnosed
as T 2.8 However, with obesity increasing in the popula-
tion and the resulting increase in T2D in the young, this
traditional distinction has become less clear.12 13
Misclassiﬁcation of diabetes has been shown to occur
in 7–15% of cases,13–15 and these studies are likely to
underestimate the problem, as they only use clinical
‘clues’ as their reference standard. The current practice
based on aetiological guidelines and clinical opinion is
clearly insufﬁcient. Pragmatic guidelines on diabetes
classiﬁcation have been developed by National Health
Service (NHS) Diabetes and The Royal College of
General Practitioners (RCGP) in the UK, but are taken
from consensus expert clinical opinion rather than
being evidence-based.13
In order to determine evidence-based criteria that
could be used to classify the two main forms of diabetes,
an appropriate gold standard is necessary. The most
important reason for correctly classifying patients is to
ensure appropriate treatment and management, and the
main factor determining this is the difference in
endogenous insulin production between patients with
T1 and T2D. Therefore, long-term insulin deﬁciency
represents an acceptable reference standard for T1D.
This is likely to be preferable to using markers of the
autoimmune process associated with T1D. While meas-
urement of various islet autoantibodies may aid discrim-
ination, these are imperfect measures,16 and most
importantly, the presence of islet autoimmunity does not
in itself determine treatment requirement.17
We aimed to systematically review the literature to
identify clinical criteria, predictive of severe insulin deﬁ-
ciency, that could be used to discriminate T1D and T2D
and inform evidence-based guidelines for the classiﬁca-
tion of diabetes.
METHODS
We followed the PRISMA guidelines for the reporting of sys-
tematic reviews. The original protocol has been published18
and is registered on PROSPERO (http://www.crd.york.ac.
uk/PROSPERO/reference CRD4201200173 6).
Data sources and search strategy
Fourteen databases were searched systematically:
MEDLINE, MEDLINE in Process, EMBASE, PsycINFO,
Social Policy and Practice, AMED, British Nursing Index,
CINAHL, HMIC, Sociological Abstracts, ASSIA,
Cochrane, Web of Science, Centre for Reviews and
Dissemination). The search strategy took the form of:
(terms for diabetes) AND (terms for C-Peptide).
Searches were limited to human only populations and
from 1979 since that was when the original classiﬁcation
scheme was proposed by the National Diabetes Data
Group.19 Searches were not limited by language or study
design.
Searches were also carried out on the Conference
Proceedings Citation Index as well as the proceedings of
the American Diabetes Association, the European
Association for the Study of Diabetes, and Diabetes UK.
BL Ethos was also searched for theses. Web-searching
was conducted, including web-site speciﬁc searches of
WHO and NICE. Forwards and backwards citation
chasing was conducted on all studies included at full-
text. The full search strategies are recorded in the
online supplementary Search Annex. Searches were ini-
tially performed in October 2012 and were updated on
3 April 2014 to capture any additional studies that may
have been carried out since the beginning of the review.
Study selection
A two-stage screening process was undertaken. In Stage
1, after removing duplicates, two reviewers (BMS and
JLP) independently screened the titles and abstracts of
all references against the inclusion and exclusion cri-
teria. In Stage 2, full texts were retrieved on all studies
included at the ﬁrst screening stage and were independ-
ently screened (by BMS and JLP). Authors of included
conference abstracts were searched to determine
whether a full article had subsequently been published.
Any discrepancies between the two reviewers were dis-
cussed and resolved by consensus, or in discussion with
a third reviewer (RJP).
Inclusion and exclusion criteria
Included studies comprised diagnostic accuracy studies
of clinical predictors of insulin deﬁciency, with the refer-
ence standard of insulin deﬁciency being deﬁned by
cut-offs of C-peptide results. All measurements of
C-peptide and all cut-offs for insulin deﬁciency were
included. Clinical predictors were deﬁned as any rou-
tinely measured clinical feature and studies were eligible
if there was a cut-off for that clinical predictor assessed
against the measure of insulin deﬁciency. There were no
restrictions on race, age or country of origin. Studies
examining islet autoantibodies only were excluded as
they are not routinely measured. A separate systematic
review examining the diagnostic accuracy of islet
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autoantibodies is presently underway (Prospero refer-
ence CRD42012001736). Studies where patients had
known causes of diabetes, for example, monogenic, sec-
ondary or syndromic diabetes, were excluded.
Data extraction
For all studies meeting the inclusion and exclusion cri-
teria, data were extracted independently by both
reviewers (BMS and JLP). Data extraction forms were
developed and piloted prior to the review. Key details of
population (age, sex, country, race, year), diabetes (def-
inition of diabetes, treatment, subgroups), reference
standard (type of sample, stimulation, assay, cut-off
used) and clinical predictors (which predictors were
included, how they were measured, the cut-offs used)
were recorded. All C-peptide cut-offs were converted to
the fasting serum equivalent to allow direct compari-
son.10 Two-by-two tables were extracted where possible
to determine the proportion of patients who were
C-peptide negative/positive (ie, below/above the
cut-off) and the sensitivity, speciﬁcity, positive and nega-
tive predictive values of the clinical characteristics at
reported cut-offs.
Quality assessment
Both reviewers (BMS and JLP) assessed quality inde-
pendently and discrepancies were resolved by consensus.
Quality assessment forms, based on the criteria set out
in QUADAS-2,20 were developed and piloted prior to
review. These criteria included assessment of internal
and external validity of patient selection, the clinical pre-
dictors and patient ﬂow and timing. Variability in the
measurements for the reference standard was assessed
separately. Further details are available in the online sup-
plementary material.
Data synthesis
Owing to the considerable heterogeneity between the
studies identiﬁed, meta-analysis, as proposed in our ori-
ginal protocol, was not appropriate. Data synthesis is,
therefore, largely descriptive with summary data pre-
sented. Criteria with a mean of sensitivity and speciﬁcity
>70% (equivalent to a receiver operating characteristic
area under curve of 0.7) were considered clinically
useful. Ranking of the discriminatory ability of criteria
within studies was used to compare their relative
performance.
Reporting bias
No formal assessment of publication bias was under-
taken due to heterogeneity between studies and the
small number of included studies. We did perform a
comprehensive and exhaustive search including grey lit-
erature, however it cannot be ruled out that our system-
atic review is affected by reporting biases.
RESULTS
Initial screening
Figure 1 shows the ﬂow diagram of citations found.
A total of 10 917 records were identiﬁed from database
searches and a further 148 sources were identiﬁed from
grey literature searches. After title and abstract screen-
ing, 194 articles were deemed potentially relevant.
Following full-text screening, nine studies were identiﬁed
as eligible based on our inclusion criteria21–29 (for
further details see online supplementary material).
Backward and forward citation searching was carried out
on the nine included references, and conference abstracts
were followed up, identifying a further 43 studies for full-
text review, one of which30 met our inclusion criteria. In
April 2014, an update search was performed yielding a
further 2101 references for screening. Thirty-six of these
were identiﬁed by the two reviewers as requiring full-text
review, and one of these ﬁtted inclusion criteria.31 Thus,
11 articles contribute to this systematic review.
Data extraction and quality assessment
There was considerable heterogeneity across the included
studies (see online supplementary table S1). The 11
included studies spanned a wide range of years (1981–
2013). Studies varied in terms of race, age group and sub-
groups of diabetes studied. One study included only
patients with end-stage renal disease,22 whereas it was a
speciﬁc exclusion criterion for another study.28 Three
studies focused on insulin-treated patients only,24 29 30
whereas the other studies either included all patients
regardless of treatment or did not report on treatment.
Sample size ranged from <10022 29 31 to >3000.25 The pro-
portion of patients classiﬁed as insulin deﬁcient (based
on the reported C-peptide cut-off in each paper) also
varied (median (range) 40% (7–69%)), reﬂecting differ-
ing inclusion criteria across studies altering the propor-
tions with different forms of diabetes across the studies.
Quality assessment of the included studies is sum-
marised in online supplementary table S2. In general,
there was a low risk of bias in terms of patient selection
and patient ﬂow/timing. Two studies were at high risk of
bias22 29 in terms of the clinical criteria used as these
were internally derived, so diagnostic performance is
likely overestimated in these cases.32 In terms of external
validity, studies were all applicable to our broad research
question but most restricted inclusion criteria to a subset
of the diabetic population.
The reference standards varied in terms of sample
provided, timing of sample in relation to meal stimula-
tion, and cut-offs for C-peptide (see online supplemen-
tary table S3). Five studies report deriving their cut-offs
from previous papers.21 22 25 29 30 Two studies derived
the cut-off used from their own data,27 28 potentially
introducing bias, although the cut-offs were comparable
to those derived from the literature. Despite the vari-
ation in measurements, all were appropriate to classify
insulin deﬁciency and cut-offs were largely comparable
with most approximating 0.2 nmol/L,21 22 24–26 28 30 and
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four studies using a slightly more conservative cut-off
(0.03–0.08 nmol/L). 23 27 29 31 Only one study measured
C-peptide and clinical features at diabetes diagnosis.31
All other studies were cross-sectional with varying dur-
ation of diabetes.
Data synthesis
Owing to the heterogeneity across studies, particularly in
terms of inclusion criteria, formal quantitative
meta-analysis was not appropriate. Therefore, data syn-
thesis is largely descriptive.
Age at diagnosis, BMI, insulin treatment/time to insulin
are consistent predictors of insulin deficiency across
studies
Age at diagnosis (9 studies), measures of obesity (includ-
ing BMI, or percentage desirable weight in earlier
studies) (8 studies) and either time to insulin treatment
Figure 1 Flow diagram showing inclusions and exclusions from title and abstract screening, and full-text review. *Follow-Up
includes full texts identified from follow-up of conference abstracts (n=29) and references identified from backwards and forwards
citation chasing (n=14).
Table 1 Criteria reported in the 11 included studies used to discriminate between C-peptide positive and negative patients
First author (year)
Age at
diagnosis
Insulin treated or
Time to insulin
BMI
(or similar) DKA
Onset (gradual
or acute)
Prior (1991) 1 2 3
Welborn (1983) 2 1 3
Laakso (1987) 3 1 2
Benhamou (1992) 1 2 3 x x
Shields (2010) 1 2 3
Service (1997) # # # # #
Boyle (1999) 1 2 3
Welborn (1981) 1 2
Nielsen (1986) 1
Ekpebegh (2013) 1 2 Inc
Balasubramanyam (2006) 1 Inc
Numbers indicate their ranking in terms of discriminatory ability within studies, with 1 representing the most discriminatory. # indicates used as
part of an algorithm, but discriminatory value of individual criteria not reported. × indicates features not discriminatory. ‘Inc’ indicates inclusion
criteria for the study, so feature could not be used to discriminate. Only features reported in more than one paper shown (see text for details
of others).
BMI, body mass index; DKA, diabetic ketoacidosis.
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(5 studies) and/or use of insulin treatment (3 studies)
were identiﬁed as consistent clinical criteria predictive
of insulin deﬁciency (table 1). In all studies reporting
these criteria, younger age at diagnosis, slimmer BMI
and shorter time to insulin was used to deﬁne insulin
deﬁciency.
Absence of each of acanthosis nigricans and hyperten-
sion were predictive of insulin deﬁciency (overall correct
classiﬁcation rates of 61% and 72%, respectively), but
these were only assessed in one study.31 Other measures
were available in four studies22 26 27 31 (including history
of diabetic ketoacidosis (DKA)22 26 or ketonuria,22
history of hypoglycaemia,27 speed of onset of diabetes,26
long-term complications,22 polyuria,22 weight loss,22
post-Sustacal glucose,27 serum creatinine,27 diabetes in a
ﬁrst-degree relative31 and history of poor control27), but
they were either not discriminatory, or they contributed
very little individual discriminatory power to an overall
algorithm.
Age at diagnosis cut-offs better predicted insulin
deficiency than cut-offs of BMI or time to insulin
When comparing discriminative ability of the most com-
monly reported criteria within studies, age at diagnosis,
at the cut-off described in the individual study, correctly
classiﬁed more patients than the other clinical features
(most discriminatory criteria in 7/9 studies). Time to
insulin/insulin treatment was the next best predictor,
and BMI (or equivalent) was the weakest of the signiﬁ-
cant predictors (table 1).
Cut-offs for age at diagnosis, BMI and time to insulin
were fairly consistent across studies
Cut-offs with the best combination of sensitivity and spe-
ciﬁcity (mean of sensitivity and speciﬁcity >70%) were
similar across studies. For predicting insulin deﬁciency,
the best cut-offs for age at diagnosis were <30 years (2
studies) or </≤40 years (4 studies). For time to insulin,
<1 year (1 study) or </≤2 years (2 studies) were the best
cut-offs, although longer cut-offs were not assessed in
any of the studies identiﬁed. For BMI, cut-offs <27 kg/m2
(1 study) and <28 kg/m2 (3 studies) were most useful
(see table 2). Extracted 2×2 tables are presented online
supplementary tables 4.
BMI cut-offs provide little improvement in classification in
addition to age at diagnosis and insulin use/time to
insulin criteria
Combinations of cut-offs did not consistently improve
the overall rate of classiﬁcation. The addition of BMI did
not improve classiﬁcation over age at diagnosis and/or
use of/time to insulin treatment in all ﬁve studies where
these combinations were reported (<1% improvement in
classiﬁcation; see table 3). The addition of insulin treat-
ment or time to insulin criteria improved classiﬁcation
over using age at diagnosis alone in 3/5 studies where
both were reported (see table 3). Extracted 2×2 tables
and summary statistics are presented in online supple-
mentary tables S4 and S5.
DISCUSSION
Principal findings
Few studies have robustly assessed utility of clinical features
in diagnosing diabetes subtype
There were only 11 appropriate studies that examined
which clinical characteristics could discriminate between
T1 and T2D, using the reference standard of insulin
deﬁciency. This is a remarkably low number of studies
considering the vast majority of the >200 million patients
with diabetes will be classiﬁed into type 1 or type 2 on
the basis of clinical features alone and an incorrect clas-
siﬁcation will result in inappropriate treatment.
Age at diagnosis was the most discriminatory clinical feature
Age at diagnosis, time to insulin and BMI consistently
emerged as the main discriminatory clinical criteria
despite the considerable heterogeneity of the included
studies. Age at diagnosis was the best discriminatory cri-
teria with diagnosis either below 30 or below 40 years
being predictive of T1D. In terms of providing useful cri-
teria for clinical practice, based on the current available
evidence, this would suggest clinicians should place
more emphasis on age than obesity when diagnosing
diabetes subtype, but exercise caution when classifying
patients diagnosed between the ages of 30 and 40 where
further investigation is likely to be necessary.
Time to insulin treatment is a useful discriminator, but
biased by physician opinion
Starting insulin treatment before 2 years did slightly
improve discrimination over age of diagnosis (table 3).
However, treatment assignment can clearly not be used
to deﬁne initial treatment, which is one of the major
reasons for determining diabetes subtype. Treatment
decisions are physician-dependent, as well as disease-
dependent, so will vary between clinicians.
BMI discriminatory but adds little over age at diagnosis
BMI provided <1% improvement in classiﬁcation over
age at diagnosis or age at diagnosis and time to insulin.
Clinicians often use obesity as a marker to indicate T2D,
but our ﬁndings suggest using this is unlikely to be
helpful over and above using age at diagnosis.
Other may not be sufficiently discriminatory
Other measures were less often studied. Acanthosis
nigricans and hypertension did discriminate C-peptide
positive from C-peptide negative patients, but these were
only assessed in one study. Other features were either
not discriminatory or only contributed weakly to an algo-
rithm, and therefore unlikely to be useful in practice.
These measures included features of diagnosis such as
diabetic ketoacidosis, ketonuria and rapid onset of symp-
toms including weight loss. In fact, in the two studies
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examining only patients presenting with DKA, 40% and
46% were C-peptide positive,21 31 suggesting DKA is not
useful in its own right for classifying a patient as having
type 1 diabetes.
Strengths and weaknesses
Strengths
We have carried out a comprehensive and robust system-
atic review in accordance with PRISMA guidelines and
our initial published protocol.18 We screened a large
number of literature sources, and all reviewing and data
extraction was carried out in duplicate independently by
two authors (BMS and JLP).
Limitations
Heterogeneity across studies could have inﬂuenced the
diagnostic performance of cut-offs identiﬁed and so pre-
cluded formal meta-analysis. There were four key areas
in particular, where heterogeneity was apparent: (1) The
proportion of insulin-deﬁcient patients varied consider-
ably across the studies (range 7–69%), reﬂecting major
differences in inclusion criteria for each study and
varying proportions of T1 and T2D in the study popula-
tions. (2) Studies spanned over 30 years (1981–2013)
and there have been considerable changes in the pheno-
type of T1 and T2D in this time. With the rising preva-
lence of obesity in the population, T1 patients are now
more likely to be obese than in the past, and T2D has
Table 2 Criteria for predicting type 1 diabetes—single criteria
Cut-off Author (year) N
Per cent
C-pep
neg
Sens
(%)
Spec
(%)
Mean sens
and spec
Per cent
correct PPV NPV
(i) Age at diagnosis (a/d)
<20 Boyle (1999) 3613 7 20 97 59 92 36 94
≤30 Prior (1991) 575 61 84 82 83 83 88 77
<30 Nielsen (1986) 215 69 64 88 76 72 92 53
<30 Ekpebegh (2013) 71 49 57 72 65 65 67 63
<39 Shields (2010) 72 56 68 97 83 81 96 70
≤40 Prior (1991) 575 61 97 59 78 82 79 92
≤40 Welborn (1983) 121 21 84 85 85 85 60 95
≤40 Welborn (1981) 201 24 76 81 79 79 55 92
≤40 Laakso* (1987) 171 67 61 79 70 67 85 44
<45 Boyle (1999) 3613 7 65 57 61 57 10 96
(ii) Insulin treatment/time to insulin (tti) (a=all treatments, i=insulin-treated only)
on insulin
(a)
Prior (1991) 575 61 99 25 62 70 68 97
on insulin
(a)
Welborn (1981) 201 24 100 70 85 77 49 100
on insulin
(a)
Boyle (1999) 3613 7 91 61 76 63 15 99
tti≤1.5 m (i) Shields (2010) 72 56 80 56 68 69 70 69
tti<1y (a) Prior (1991) 575 61 92 75 84 85 85 85
tti<2y (a) Welborn (1983) 121 21 100 82 91 86 60 100
tti≤2y (i) Laakso* (1987) 90 67 70 86 78 75 91 58
(iii) BMI
<20 Boyle (1999) 3613 7 10 98 54 92 33 94
<25† Prior (1991) 575 61 34 92 63 57 87 47
<25 Boyle (1999) 3613 7 41 86 64 83 18 95
<27† Prior (1991) 575 61 87 63 75 78 79 76
≤27† Welborn (1983) 121 21 80 67 74 69 38 93
≤27 Laakso* (1987) 90 67 76 66 71 73 82 57
<28 Balasumbryaman
(2006)
294 60 67 86 77 78 79 77
<29 Boyle (1999) 3613 7 71 57 64 58 11 96
<29 Shields (2010) 72 56 78 56 67 68 69 67
<30 Ekpebegh (2013) 71 49 77 47 62 62 59 68
Sensitivity (sens), specificity (spec), proportion correctly classified (%correct), mean of sensitivity and specificity (mean sens and spec),
positive predictive value (PPV), and negative predictive value (NPV) for (i) age at diagnosis, (ii) body mass index (BMI) and (iii) insulin
treatment and/or time to insulin. Proportion of C-peptide negative patients (% C-pep neg) shown to aid interpretation of % correct, PPV and
NPV. Criteria with a mean sensitivity and specificity >70% are highlighted in bold.
*Male and female values combined, using postglucagon-stimulated results.
†Converted from percentage desirable weight.
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become more common in young adults. (3) Renal
disease is known to impact on C-peptide clearance, so
differences were likely in the studies excluding patients
with renal disease,25 28 compared with those exclusively
examining those with ESRD.22 (4) Ethnicity differed
across studies, from populations that were predomin-
antly Caucasian,23 27 to those predominantly Hispanic
and/or Black African31/African-American patients.21 25
Despite the considerable differences in studies, however,
there were consistencies in the criteria identiﬁed and
the most discriminatory cut-offs across the different
populations.
The small number of studies and the heterogeneity
between them means there is still uncertainty around
the usefulness of the criteria and cut-offs proposed, and
highlights a clear need for further work in this area.
This review provides a strong starting point from which
to develop future prediction criteria.
Differences in the reference standards (eg, in the
samples, stimuli, assay used and cut-offs used) high-
lighted problems with our reference standard for T1D.
However, although cut-offs were derived in a variety of
ways, they were largely comparable and appropriate for
detecting insulin deﬁciency in the populations of inter-
est. Where more than one cut-off was used,24 26 27 30 this
made little difference (<12%) to the proportion of
patients classiﬁed and the cut-offs identiﬁed. These dif-
ferences represent potential issues with using our ‘gold
standard’ for insulin deﬁciency when aiming to classify
T2D. We would therefore suggest caution in future
studies when classifying patients close to the proposed
C-peptide cut-off.
Other forms of diabetes
We have only considered the two main forms of diabetes
for which there are clear national and international
treatment guidelines. Rarer subtypes are not considered
here. Other forms of diabetes, such as latent auto-
immune diabetes of adults, are not included in inter-
national guidelines and appropriate treatment would be
guided by insulin deﬁciency, our gold standard. Further
work would be needed to derive criteria for a ‘grey area’
where diagnosis of subtype is less certain and further
investigations would be required to aid classiﬁcation.
Implications and future work
Evidence-based guidelines on the classiﬁcation of T1D
and T2D need to include clinical criteria on how the
diagnosis should be made. This is a major omission in
current national and international guidelines for dia-
betes. The evidence as identiﬁed in this review suggests
age at diagnosis and time to insulin (when available) are
essential components as they contribute most to the pre-
dictive ability. BMI, and other clinical criteria, do not
appear to add to add further discrimination. The cri-
teria identiﬁed are similar to the RCGP/NHS Diabetes
Guidelines for Classiﬁcation13 which are based on con-
sensus expert opinion. These guidelines would
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therefore, represent a suitable classiﬁcation scheme
until a stronger evidence base is available.
New studies are urgently needed to further develop
and validate criteria suitable for classifying diabetes. We
identiﬁed no studies in the Asian or paediatric popula-
tions, and only one study assessing features close to diag-
nosis.31 Determining classiﬁcation rules for both the
incident and prevalent population would be important.
Labelling a patient’s diabetes at the outset is crucial as
the classiﬁcation given is rarely reconsidered. The evi-
dence in this review should be used to redevelop a clin-
ical prediction tool for T1D and T2D. C-peptide is likely
to be less discriminatory at diagnosis, as patients with
T1D can still produce their own insulin in the ‘honey-
moon’ period, so it would be important to examine pre-
dictors of insulin deﬁciency after this time. Future
studies should be large-scale, prospective and give results
for all racial and age groups using follow-up C-peptide
measurements at least 3 years after diagnosis as an
outcome. These studies would help answer if clinical cri-
teria used in combination are sufﬁcient to accurately
classify diabetes, or whether investigations, such as islet
autoantibodies, are needed in addition. Consideration
of other forms of diabetes, such as monogenic diabetes,
is also important.
We did not include antibodies in our search criteria as
we limited our review to routinely available clinical cri-
teria. Antibodies may represent a useful test at diagnosis,
where C-peptide is of limited value due to the ‘honey-
moon period’, where patients with T1D are still able to
produce signiﬁcant amounts of their own insulin for a
short period of time. A systematic review examining the
use of antibodies at predicting long-term insulin deﬁ-
ciency is presently in progress (Prospero reference
CRD42012001736)
In conclusion, we have performed the ﬁrst systematic
review of the literature that examines using clinical cri-
teria for the classiﬁcation of diabetes. Although, only 11
studies were identiﬁed, age at diagnosis and time to
insulin were consistent as discriminatory criteria across
studies. BMI did not aid classiﬁcation over these factors.
The discriminatory criteria identiﬁed were similar to
those proposed by the RCGP/NHS Diabetes
Classiﬁcation guidelines, so these would represent a suit-
able classiﬁcation scheme at present. New studies are
urgently needed to assess and validate the most appro-
priate clinical criteria. This review provides a summary
of the current knowledge base for reference in any
future studies developing classiﬁcation rules.
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